COMPANY OVERVIEW

None

---

LOCATION

---

THERAPEUTIC AREAS

---

WEBSITE

None

---

CAREER WEBSITE

None

---

SOCIAL MEDIA

---

INVESTORS

---

PRESS RELEASES

Sep 15, 2022

Cytovation Strengthens its Board of Directors for Next Phase of Development

May 19, 2022

US FDA accepts Cytovation's IND application for Phase II combination studies of CyPep-1, a first-in-class targeted tumor membrane immunotherapy

Feb 8, 2022

Cytovation collaborates with Recurrent Respiratory Papillomatosis Foundation to expand its clinical investigations of CyPep-1 into rare neoplastic disease

Jan 25, 2022

Cytovation raises $20 million in Series A financing round to advance clinical development of CyPep-1, a first-in-class targeted tumor membrane immunotherapy

Nov 15, 2021

First Patient Dosed with CyPep-1 in Combination with KEYTRUDA in Cytovation's Ph I/IIa CICILIA Clinical Trial

For More Press Releases

---